New York, February 9, 2026, 14:33 EST — Regular session
- Thermo Fisher stock edged 0.1% higher in the afternoon, fluctuating between $537.13 and $547.99.
- The company is pitching a four-part senior notes deal, but so far, the preliminary prospectus hasn’t shared any terms.
- The money’s earmarked for the planned Clario deal. Pricing and leverage remain squarely on investors’ radar.
Thermo Fisher Scientific inched higher Monday, with shares up 0.1% at $543.48 in afternoon trade, following news of a fresh multi‑tranche bond filing. The offering comes as the company seeks funding for its pending Clario acquisition.
Thermo Fisher’s preliminary prospectus supplement sketches out four tranches of senior notes, but skips over the details—no principal, coupon, or maturity numbers yet. The company also dropped a look at expected 2025 numbers, noting consolidated debt for it and its subsidiaries stood at around $39.38 billion as of December 31, 2025.
What’s at stake right now: Thermo Fisher wants to keep its funding plan under wraps while investors eye the numbers on deal leverage and interest expenses. The company said it plans to finance the Clario acquisition—tagged at roughly $8.875 billion in cash at closing, with additional deferred and contingent payments—using both debt and cash on hand.
Stocks across the board pushed higher, though healthcare names sank. The S&P 500 ETF tacked on roughly 0.7%, but the Health Care Select Sector SPDR dropped 0.9%.
Bondholders are zeroing in on the usual safeguards built into the notes. According to the prospectus, if there’s a “change of control” — generally triggered by specific takeovers or changes in ownership — investors will have the right to sell the notes back at 101% of face value. The document also spells out optional redemption conditions. StreetInsider.com
Credit markets flashed a green light. On Monday, S&P Global Ratings tagged the planned senior unsecured debt with an ‘A-’ issue-level rating, per its latest press releases.
In a separate disclosure from the bond filing, a Form 144 notice indicated that Gianluca Pettiti, a company executive, intends to offload 400 shares of Thermo Fisher. The filing puts the total market value at $216,480.
Thermo Fisher’s investor relations page lists Pettiti as executive vice president and president of Life Sciences, Diagnostics and Applied.
Life sciences tools stocks saw uneven moves this day: Danaher edged up 0.1%, but Agilent dropped 1.7% and Illumina lost around 2.3%.
Still, the funding isn’t without its pitfalls. Thermo Fisher’s own prospectus makes clear: the bond sale doesn’t depend on the Clario deal actually happening. A change in credit markets? That could impact how much they end up paying to borrow.
Stock investors are eyeing the bond pricing next — specifics like size, coupons, and maturities are still to come in a follow-up filing once the deal gets finalized. Once that lands, the focus shifts to regulatory sign-off and any fresh timeline for Clario.
